Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Predictions

buy
Universal Health Services B

Start price
Target price
Perf. (%)
€117.92
06.03.23
€135.81
06.03.24
37.38%
07.03.24

buy
Seagen Inc.

Start price
Target price
Perf. (%)
€165.86
06.03.23
€173.60
06.03.24
26.85%
07.03.24

buy
Eli Lilly Corp.

Start price
Target price
Perf. (%)
€299.80
03.03.23
€339.30
03.03.24
142.83%
04.03.24

buy
Universal Health Services B

Start price
Target price
Perf. (%)
€120.22
03.03.23
€143.96
03.03.24
33.92%
04.03.24

buy
Seagen Inc.

Start price
Target price
Perf. (%)
€167.56
28.02.23
€159.97
28.02.24
25.57%
29.02.24

buy
UCB S.A.

Start price
Target price
Perf. (%)
€80.98
22.02.23
€95.00
22.02.24
18.18%
23.02.24

Could be worthwhile Investment >10% per year
buy
Eli Lilly Corp.

Start price
Target price
Perf. (%)
€529.00
18.12.23
€558.00
18.12.24
6.62%
06.01.24

Higher EBIT margin than peer group
Differentiated customer and product portfolio
Medium risks for its business
Top 10 in its market
buy
Exact Sciences

Start price
Target price
Perf. (%)
€62.80
20.04.23
€65.50
03.05.24
9.71%
27.12.23

Bayer AG

Start price
Target price
Perf. (%)
€32.77
24.11.23
€35.00
21.12.23
-6.78%
29.11.23

Sustainability is little important
high free float
Higher risks for its business
Below average Marketposition
Bayer AG

Start price
Target price
Perf. (%)
€40.83
15.11.23
€35.00
15.11.24
-19.02%
22.11.23

Probably not worthwhile Investment
Higher risks for its business
buy
Amgen Inc.

Start price
Target price
Perf. (%)
€246.80
19.09.23
€250.00
19.09.24
4.13%
27.09.23

Could be worthwhile Investment >10% per year
High dividend yield expected
positive Cash Flow expected
Good rating
buy
Eli Lilly Corp.

Start price
Target price
Perf. (%)
€502.50
17.08.23
€510.00
17.08.24
10.75%
13.09.23

Higher EBIT margin than peer group
Differentiated customer and product portfolio
Medium risks for its business
Top 10 in its market
buy
Johnson & Johnson

Start price
Target price
Perf. (%)
€152.60
24.07.23
€155.00
24.07.24
3.47%
16.08.23

High dividend yield expected
positive Cash Flow expected
Good rating
Standard Investments for future growth
buy
Novo Nordisk A/S

Start price
Target price
Perf. (%)
€100.76
08.08.22
€120.00
08.08.23
69.31%
09.08.23

buy
EssilorLuxottica SA

Start price
Target price
Perf. (%)
€146.15
15.07.22
€175.00
15.07.23
21.16%
16.07.23

buy
Eli Lilly Corp.

Start price
Target price
Perf. (%)
€388.00
05.05.23
€395.00
05.05.24
3.52%
12.05.23

Higher EBIT margin than peer group
Differentiated customer and product portfolio
Medium risks for its business
Top 10 in its market
buy
Seagen Inc.

Start price
Target price
Perf. (%)
€165.90
15.08.22
€180.00
31.01.24
9.64%
08.05.23

Could be very worthwhile Investment >20% year
buy
Intuitive Surgical Inc

Start price
Target price
Perf. (%)
€233.45
25.04.22
€250.00
25.04.23
14.61%
26.04.23

Could be worthwhile Investment >10% per year
Fair valuation
Some uniques
Higher risks for its business
Merck KGaA

Start price
Target price
Perf. (%)
€190.20
23.01.23
€175.00
23.04.23
-12.41%
23.04.23

Some uniques
Future proof or reliable business model
overvalued
Low dividend yield expected
buy
Seagen Inc.

Start price
Target price
Perf. (%)
€152.08
07.09.22
€180.00
31.12.24
21.00%
21.03.23

Could be very worthwhile Investment >20% year
buy
UnitedHealth Group Inc.

Start price
Target price
Perf. (%)
€407.05
24.01.22
€418.00
24.01.23
10.66%
25.01.23

Could be worthwhile Investment >10% per year
buy
Biogen Inc.

Start price
Target price
Perf. (%)
€208.25
27.12.21
€215.00
27.12.22
23.82%
28.12.22

Could be worthwhile Investment >10% per year
buy
Johnson & Johnson

Start price
Target price
Perf. (%)
€140.70
27.11.21
€160.00
27.11.22
21.35%
28.11.22

Could be worthwhile Investment >10% per year
Significant cyclical dependencies
buy
Astrazeneca ADR

Start price
Target price
Perf. (%)
€50.60
27.11.21
€60.00
27.11.22
26.48%
28.11.22

Could be worthwhile Investment >10% per year
Significant cyclical dependencies
buy
Regeneron Pharmaceuticals Inc.

Start price
Target price
Perf. (%)
€533.60
09.11.21
€600.00
09.11.22
38.91%
10.11.22

Could be worthwhile Investment >10% per year